Last reviewed · How we verify
NCT06994819
Evaluation of the Niostem Headset for Hair Growth and Hair Quality
NA trial testing niostem headset (Active) in Androgenetic Alopecia in 101 participants. Completed in 30 September 2024.
30 September 2024
Quick facts
| Lead sponsor | Mane Biotech GmbH |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 101 |
| Start date | 1 October 2023 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- niostem headset (Active)
- Sham niostem headset (Placebo)
Conditions studied
- Androgenetic Alopecia — all drugs for Androgenetic Alopecia →
- Pattern Baldness — all drugs for Pattern Baldness →
Sponsor
Mane Biotech GmbH
Who can join
Adults 18 to 55, any sex, with Androgenetic Alopecia or Pattern Baldness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This double-blind, randomized, placebo-controlled clinical trial evaluates the Niostem headset, an electronic device designed to support hair growth, reduce hair loss, and improve hair quality. A total of 101 adult participants (20 female, 81 male) aged 18-55 were enrolled. Participants used the device daily for 30 minutes over a six-month period. The primary objective is to assess skin tolerability, and secondary objectives include evaluating usability and efficacy through validated questionnaires, TrichoScan hair analysis, and digital imaging under dermatological supervision.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy, Safety, and Tolerability of a Wearable Electrotrichogenic Device in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Sham-Controlled Trial.
Chacón-Martínez CA, Pogorelov G, Cabral KK, Emmler T, et al · · 2026 · PMID 42018094 · DOI 10.1007/s13555-026-01747-5
Verify or expand the search:
- PubMed search for NCT06994819
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Androgenetic Alopecia
Currently open trials in the same condition.
- NCT07429253 — Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients · Phase 1, PHASE2 · recruiting
- NCT06841458 — Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06994819 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mane Biotech GmbH
- Last refreshed: 22 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06994819.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing